Feedback plc – “NHS Progress and Business Update” = NHS potential for “widescale” business delayed!

Digital healthcare technology company Feedback (FDBK) has issued an “NHS Progress and Business Update”-titled announcement including that “discussions have continued to progress positively with central NHS stakeholders regarding at scale opportunities for Bleepa” and that “NHSE has extended Bleepa’s existing licences at Queen Victoria Hospital NHS Foundation Trust (annualised contract value £495k)… The Bleepa pathway use case is also being demonstrated for internal pathways at the Northern Care Alliance NHS Foundation Trust where the company has agreed a further annual contract extension”. So what about a current share price response towards 11p, more than 20% down?

Feedback plc – full-year results argue “remain well positioned to generate strong returns”. Is it though?…

Most recently on medical data technology company Feedback plc (FDBK), in April with the shares falling below 14p I noted with it having previously argued “well placed for contract awards and selection within key government initiatives in 2025” that it was, quelle surprise, “increased levels of near-term uncertainty and a delay in expected contract awards” and concluded avoid/sell. The shares most recently closed at 13.25p and what about them currently falling below 12p on results for the company’s year ended 31st May 2025?

Feedback plc – I having cautioned on its two months ago-argued “well placed for contract awards and selection within key government initiatives in 2025”, now Quelle Surprise…

Most recently writing on medical data technology company Feedback plc (FDBK), in February, with the shares falling to below 18p and it argued its “relationships and proven technology ensure that Feedback is positioned to scale up delivery”, I continued to question that and concluded to still avoid. The shares most recently closed at 17.5p and now a “Trading Update” and what about the shares currently falling below 14p?

Feedback (#FDBK) – “Trading Update” = trading warning

Feedback plc – interims, how well really is it “positioned to scale up delivery”?

Most recently writing on medical data technology company Feedback plc (FDBK) I suggested that, despite a recent fundraising, its outlook didn’t bode well for ‘building scale for implementation’ and the ‘runway for delivery’. So what of today half-year ended 30th November 2024 results and the shares currently back below 18p in response?

Feedback plc – trading update, how substantial really is its “runway for delivery”?

Medical data technology company Feedback plc (FDBK) has issued a “trading update” including “cash and cash equivalents as at 30 November 2024 were c.£7.3m (30 November 2023: £5.4m)” and that it believes its 'Bleepa' product is perfectly aligned with NHS digitisation and shift to delivery of care in communities. So what of a share price up to just 17p comparing to above 60p as recently as October?!

Feedback (#FDBK) – argues “growing pipeline of opportunities” but H1 revenue only “expected to be broadly flat”

Feedback plc – argues “successful fundraising”. Er, what about the 55% discount?!

Most recently writing on medical data technology company Feedback plc (FDBK), last month with the shares up to above 55p I concluded then including ‘no results detail with the announcement having been on 12th September last year, 20th September the year before that but in November the year before that…when it was accompanied by a fundraise. I ask how’s the balance sheet position now and is the company’s latest attempted ramptastic?’. Today results for its year ended 31st May 2024 and a stated “successful fundraising”.

Feedback (#FDBK) – proposed bailout fundraising for up to £6.3m

Feedback (#FDBK) – FY loss £3.3m, cash down to £3.9m

Feedback plc – emphasises now Elective Recovery Fund reimbursement eligibility, but balance sheet detail that dare not speak its name?

Medical data technology company Feedback plc (FDBK) has announced its ‘Bleepa’ platform is “now eligible for reimbursement under the Elective Recovery Fund and that any Integrated Care Board or hospital in England will, with immediate effect be able to utilise this funding, by local agreement, to reimburse expenditure on the Bleepa technology… Management believes that access to ERF represents a step change in the company's commercial prospects”. What of a share price currently soaring back above 55p in response?

Feedback plc – contract award, a “compelling validation” of its technology?

Medical data technology company Feedback plc (FDBK) has announced a contract award which it argues “is a compelling validation of our technology”. Does it look sufficiently compelling to justify a current more than 10% share price rise to above 80p?

Feedback – trading update argues set to “build on the fantastic foundation that we have built”. Er, what about that continuing cash burn?

Data technology for clinicians company Feedback (FDBK) has issued a trading update with CEO Dr Tom Oakley emphasising “despite a delay in some of our larger national and regional NHS opportunities we have delivered revenue growth in FY2024 and optimised our cost base” and that those delays have also “given us an opportunity to continue pursuing our international opportunities and we are making promising progress in India around TB screening and other upcoming opportunities that have been unlocked by our in-country MD, Rohit Singh, having established the right to sell Bleepa as a medical device”. So what about a share price currently of 67.5p in response, down more than 8%?

Feedback – interims and argues pilot agreement importance “cannot be understated”. What about cash burn importance?…

Medical device company Feedback plc (FDBK) has announced results for its half-year ended 30th November 2023 with CEO Dr Tom Oakley “delighted with the increased traction for our core products” and considering that the “outlook is promising”. So why currently a slightly lower to 61p share price, just above £8 million market capitalisation, and with the shares down from above 100p just last summer?

Feedback (#FDBK) – trading decline “half year trading update”

Feedback (#FDBK) – emphasises “potential” and growth but H1 revenue c.£0.6m and continued cash burn

Feedback – back the bookbuild or – after disastrous results – it’s a crash landing in tits up alley

There are a few things that I disagree with Comrade Malcom Stacey about: all this green shite from COP26 for starters. Just how great meat tastes is another. And whether the Guardian newspaper has any useful purpose other than to light a fire is a third. A fourth is Feedback (FDBK) which he keeps tipping and which I regard as a cash guzzling, jam tomorrow generating, worthless piece of crap which serves only to enrich City financiers and has two decades of failure to boast about. So today we have (dire) results and a £10.5 million or more fund raise. A bookbuild is underway.

Feedback (#FDBK) – proposed minimum £10m placing & just £0.5m open offer at 0.7p per share

Medical Pioneer Feedback Shows Another Sign of Sunnier Prospects

Hello, Share Smirkers. Though Uncle Tom ain’t a fan, I still like the look of medical pioneer Feedback (FDBK). It’s one of those companies with a blistering idea which has so far not brought in the sheaves (forgive the expression, but it is harvest festival time). Perhaps the times are a changing, though. The London company has this week agreed a memorandum of understanding with an artificial intelligence set-up called Quest Teleradiology. This is a India-based diagnostic service with healthcare clients across India, the UK and Africa.

New Accolade for Feedback Could Bring in Customers and Galvanise the Share Price at Last

Hello, Share Speakers. Though Uncle Tom has reservations about this share, I still rather like the prospects of Feedback plc (FDBK), a company that helps hospital doctors keep in touch with information they need and with each other while on the hoof.